Arcadia Biosciences (RKDA) Stock Forecast, Price Target & Predictions
RKDA Stock Forecast
Arcadia Biosciences stock forecast is as follows: an average price target of $6.00 (represents a 106.90% upside from RKDA’s last price of $2.90) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
RKDA Price Target
The average price target for Arcadia Biosciences (RKDA) is $6.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 106.90% upside from RKDA's last price of $2.90.
RKDA Analyst Ratings
According to 1 Wall Street analysts, Arcadia Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for RKDA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Arcadia Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 23, 2024 | Raghuram Selvaraju | H.C. Wainwright | $6.00 | $2.78 | 115.83% | 106.90% |
The latest Arcadia Biosciences stock forecast, released on May 23, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $6.00, which represents a 115.83% increase from the stock price at the time of the forecast ($2.78), and a 106.90% increase from RKDA last price ($2.90).
Arcadia Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $6.00 |
| Last Closing Price | $2.90 | $2.90 | $2.90 |
| Upside/Downside | -100.00% | -100.00% | 106.90% |
In the current month, the average price target of Arcadia Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arcadia Biosciences's last price of $2.90. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 23, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Arcadia Biosciences's last stock rating was published by H.C. Wainwright on May 23, 2024. The company gave RKDA a "Buy" rating, the same as its previous rate.
Arcadia Biosciences Financial Forecast
Arcadia Biosciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $1.60M | $1.39M | $1.51M | $1.00M | $1.88M | $3.86M | $3.22M | $2.17M | $2.38M | $1.41M | $828.00K | $7.13M | $314.00K | $281.00K | $309.00K | $416.00K | $392.00K | $203.00K | $158.00K | $436.00K | $1.02M |
| Avg Forecast | $1.75M | $1.85M | $1.55M | $1.40M | $1.40M | $1.40M | $950.00K | $1.20M | $1.75M | $1.55M | $1.60M | $1.40M | $2.00M | $2.67M | $2.30M | $1.90M | $3.33M | $2.51M | $1.69M | $734.33K | $1.26M | $1.14M | $1.86M | $800.00K | $590.00K | $283.33K | $220.00K | $325.00K | $280.99K | $714.00K |
| High Forecast | $1.75M | $1.85M | $1.55M | $1.40M | $1.40M | $1.40M | $950.00K | $1.20M | $1.75M | $1.55M | $1.60M | $1.40M | $2.00M | $2.67M | $2.45M | $2.02M | $3.54M | $2.67M | $1.80M | $781.21K | $1.34M | $1.21M | $1.97M | $851.06K | $627.66K | $301.42K | $234.04K | $345.74K | $337.19K | $856.80K |
| Low Forecast | $1.75M | $1.85M | $1.55M | $1.40M | $1.40M | $1.40M | $950.00K | $1.20M | $1.75M | $1.55M | $1.60M | $1.40M | $2.00M | $2.67M | $2.15M | $1.78M | $3.12M | $2.35M | $1.58M | $687.46K | $1.18M | $1.07M | $1.74M | $748.94K | $552.34K | $265.25K | $205.96K | $304.25K | $224.79K | $571.20K |
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 7 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.03% | 0.87% | 1.08% | 0.50% | 0.70% | 1.68% | 1.70% | 0.65% | 0.95% | 0.83% | 1.13% | 5.68% | 0.28% | 0.15% | 0.39% | 0.71% | 1.38% | 0.92% | 0.49% | 1.55% | 1.43% |
Arcadia Biosciences's average Quarter revenue forecast for Dec 23 based on 1 analysts is $1.75M, with a low forecast of $1.75M, and a high forecast of $1.75M. RKDA's average Quarter revenue forecast represents a 9.58% increase compared to the company's last Quarter revenue of $1.60M (Sep 23).
Arcadia Biosciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 7 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-3.24M | $-8.15M | $-4.09M | $-5.95M | $-6.32M | $-5.28M | $-4.81M | $-8.08M | $-2.85M | $-4.98M | $2.32M | $9.04M | $-6.15M | $-9.59M | $2.62M | $-6.19M | $-14.13M | $4.28M | $-12.56M | $-6.61M | $-3.79M |
| Avg Forecast | $-1.75M | $-1.85M | $-1.55M | $-1.40M | $-1.40M | $-1.40M | $-950.00K | $-1.20M | $-1.75M | $-1.55M | $-1.60M | $-1.40M | $-2.00M | $-3.97M | $-2.30M | $-5.50M | $-3.33M | $-2.51M | $-1.69M | $-734.33K | $-1.26M | $-1.14M | $-1.86M | $-800.00K | $-590.00K | $-283.33K | $-220.00K | $-15.82M | $-3.16M | $-2.38M |
| High Forecast | $-1.75M | $-1.85M | $-1.55M | $-1.40M | $-1.40M | $-1.40M | $-950.00K | $-1.20M | $-1.75M | $-1.55M | $-1.60M | $-1.40M | $-2.00M | $-3.18M | $-2.15M | $-4.40M | $-3.12M | $-2.35M | $-1.58M | $-687.46K | $-1.18M | $-1.07M | $-1.74M | $-748.94K | $-552.34K | $-265.25K | $-205.96K | $-12.65M | $-2.53M | $-1.90M |
| Low Forecast | $-1.75M | $-1.85M | $-1.55M | $-1.40M | $-1.40M | $-1.40M | $-950.00K | $-1.20M | $-1.75M | $-1.55M | $-1.60M | $-1.40M | $-2.00M | $-4.77M | $-2.45M | $-6.59M | $-3.54M | $-2.67M | $-1.80M | $-781.21K | $-1.34M | $-1.21M | $-1.97M | $-851.06K | $-627.66K | $-301.42K | $-234.04K | $-18.98M | $-3.79M | $-2.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.10% | 5.10% | 2.92% | 2.97% | 1.59% | 2.29% | 0.87% | 2.43% | 1.14% | 2.95% | -3.16% | -7.20% | 5.38% | 5.16% | -3.27% | 10.49% | 49.87% | -19.45% | 0.79% | 2.09% | 1.59% |
0 analysts predict RKDA's average Quarter EBITDA for Jun 21 to be $-1.69M, with a high of $-1.58M and a low of $-1.80M. This is -172.71% lower than Arcadia Biosciences's previous annual EBITDA (Mar 21) of $2.32M.
Arcadia Biosciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 7 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 12 |
| Net Income | - | - | - | - | - | - | - | - | - | $-2.57M | $823.00K | $-3.85M | $-4.33M | $-2.88M | $-3.78M | $-4.47M | $-9.55M | $-2.84M | $-5.26M | $2.06M | $8.90M | $-6.39M | $-9.69M | $2.52M | $-6.24M | $-14.19M | $4.24M | $-12.61M | $-6.67M | $-4.22M |
| Avg Forecast | $-436.11K | $-408.85K | $-54.51K | $-885.85K | $-926.73K | $-1.10M | $2.11M | $-3.02M | $-3.52M | $-3.99M | $-6.60M | $-8.99M | $-9.27M | $-3.95M | $-15.81M | $-5.70M | $-16.35M | $-16.08M | $-14.90M | $4.36M | $-22.35M | $-29.62M | $-31.98M | $5.74M | $-31.35M | $-41.98M | $-49.33M | $-15.88M | $-3.18M | $-2.65M |
| High Forecast | $-436.11K | $-408.85K | $-54.51K | $-885.85K | $-926.73K | $-1.10M | $2.11M | $-3.02M | $-3.52M | $-3.99M | $-6.60M | $-8.99M | $-9.27M | $-3.16M | $-14.50M | $-4.56M | $-15.00M | $-14.75M | $-13.66M | $5.23M | $-20.50M | $-27.16M | $-29.33M | $6.89M | $-28.74M | $-38.49M | $-45.24M | $-12.71M | $-2.55M | $-2.12M |
| Low Forecast | $-436.11K | $-408.85K | $-54.51K | $-885.85K | $-926.73K | $-1.10M | $2.11M | $-3.02M | $-3.52M | $-3.99M | $-6.60M | $-8.99M | $-9.27M | $-4.74M | $-17.12M | $-6.84M | $-17.71M | $-17.42M | $-16.14M | $3.49M | $-24.21M | $-32.08M | $-34.64M | $4.59M | $-33.95M | $-45.46M | $-53.43M | $-19.06M | $-3.82M | $-3.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.64% | -0.12% | 0.43% | 0.47% | 0.73% | 0.24% | 0.78% | 0.58% | 0.18% | 0.35% | 0.47% | -0.40% | 0.22% | 0.30% | 0.44% | 0.20% | 0.34% | -0.09% | 0.79% | 2.09% | 1.59% |
Arcadia Biosciences's average Quarter net income forecast for Sep 23 is $-3.99M, with a range of $-3.99M to $-3.99M. RKDA's average Quarter net income forecast represents a -585.19% decrease compared to the company's last Quarter net income of $823.00K (Jun 23).
Arcadia Biosciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 7 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 12 |
| SG&A | - | - | - | - | - | - | - | - | - | $3.44M | $3.81M | $4.39M | $4.21M | $4.83M | $4.65M | $4.35M | $6.19M | $6.31M | $6.37M | $4.07M | $4.78M | $4.29M | $3.67M | $3.72M | $3.13M | $4.48M | $3.15M | $2.81M | $2.95M | $3.05M |
| Avg Forecast | $7.55M | $7.98M | $6.69M | $6.04M | $6.04M | $6.04M | $4.10M | $5.18M | $7.55M | $6.67M | $6.90M | $6.04M | $8.63M | $11.51M | $9.92M | $8.19M | $14.38M | $10.82M | $7.29M | $3.17M | $5.42M | $4.93M | $8.01M | $3.45M | $2.55M | $1.22M | $949.22K | $1.40M | $1.21M | $3.08M |
| High Forecast | $7.55M | $7.98M | $6.69M | $6.04M | $6.04M | $6.04M | $4.10M | $5.18M | $7.55M | $6.67M | $6.90M | $6.04M | $8.63M | $11.51M | $10.56M | $8.72M | $15.29M | $11.51M | $7.75M | $3.37M | $5.77M | $5.24M | $8.52M | $3.67M | $2.71M | $1.30M | $1.01M | $1.49M | $1.45M | $3.70M |
| Low Forecast | $7.55M | $7.98M | $6.69M | $6.04M | $6.04M | $6.04M | $4.10M | $5.18M | $7.55M | $6.67M | $6.90M | $6.04M | $8.63M | $11.51M | $9.29M | $7.67M | $13.46M | $10.13M | $6.82M | $2.97M | $5.07M | $4.61M | $7.50M | $3.23M | $2.38M | $1.14M | $888.63K | $1.31M | $969.89K | $2.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.52% | 0.55% | 0.73% | 0.49% | 0.42% | 0.47% | 0.53% | 0.43% | 0.58% | 0.87% | 1.28% | 0.88% | 0.87% | 0.46% | 1.08% | 1.23% | 3.66% | 3.31% | 2.01% | 2.43% | 0.99% |
Arcadia Biosciences's average Quarter SG&A projection for Dec 23 is $7.55M, based on 1 Wall Street analysts, with a range of $7.55M to $7.55M. The forecast indicates a 119.30% rise compared to RKDA last annual SG&A of $3.44M (Sep 23).
Arcadia Biosciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Jun 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 7 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 12 |
| EPS | - | - | - | - | - | - | - | - | - | $-1.89 | $0.61 | $-4.49 | $-7.22 | $-4.69 | $-6.81 | $-8.07 | $-0.43 | $-0.10 | $-0.24 | $0.11 | $0.83 | $-0.60 | $-1.04 | $0.29 | $-0.72 | $-2.04 | $0.84 | $-2.64 | $-2.02 | $-2.00 |
| Avg Forecast | $-0.32 | $-0.30 | $-0.04 | $-0.65 | $-0.68 | $-0.81 | $1.55 | $-2.21 | $-2.58 | $-2.93 | $-4.84 | $-6.60 | $-6.80 | $-8.40 | $-11.60 | $-13.60 | $-12.00 | $-11.80 | $-10.93 | $-13.73 | $-16.40 | $-21.73 | $-23.47 | $-21.80 | $-23.00 | $-30.80 | $-36.20 | $-32.40 | $-0.62 | $-0.88 |
| High Forecast | $-0.32 | $-0.30 | $-0.04 | $-0.65 | $-0.68 | $-0.81 | $1.55 | $-2.21 | $-2.58 | $-2.93 | $-4.84 | $-6.60 | $-6.80 | $-8.40 | $-10.64 | $-12.47 | $-11.00 | $-10.82 | $-10.03 | $-12.59 | $-15.04 | $-19.93 | $-21.52 | $-19.99 | $-21.09 | $-28.24 | $-33.20 | $-29.71 | $-0.49 | $-0.70 |
| Low Forecast | $-0.32 | $-0.30 | $-0.04 | $-0.65 | $-0.68 | $-0.81 | $1.55 | $-2.21 | $-2.58 | $-2.93 | $-4.84 | $-6.60 | $-6.80 | $-8.40 | $-12.56 | $-14.73 | $-13.00 | $-12.78 | $-11.84 | $-14.87 | $-17.76 | $-23.54 | $-25.41 | $-23.61 | $-24.91 | $-33.36 | $-39.20 | $-35.09 | $-0.74 | $-1.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.65% | -0.13% | 0.68% | 1.06% | 0.56% | 0.59% | 0.59% | 0.04% | 0.01% | 0.02% | -0.01% | -0.05% | 0.03% | 0.04% | -0.01% | 0.03% | 0.07% | -0.02% | 0.08% | 3.26% | 2.27% |
According to 0 Wall Street analysts, Arcadia Biosciences's projected average Quarter EPS for Sep 23 is $-2.93, with a low estimate of $-2.93 and a high estimate of $-2.93. This represents a -580.33% decrease compared to RKDA previous annual EPS of $0.61 (Jun 23).
RKDA Forecast FAQ
Is Arcadia Biosciences a good buy?
Yes, according to 1 Wall Street analysts, Arcadia Biosciences (RKDA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of RKDA's total ratings.
What is RKDA's price target?
Arcadia Biosciences (RKDA) average price target is $6 with a range of $6 to $6, implying a 106.90% from its last price of $2.9. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Arcadia Biosciences stock go up soon?
According to Wall Street analysts' prediction for RKDA stock, the company can go up by 106.90% (from the last price of $2.9 to the average price target of $6), up by 106.90% based on the highest stock price target, and up by 106.90% based on the lowest stock price target.
Can Arcadia Biosciences stock reach $4?
RKDA's average twelve months analyst stock price target of $6 supports the claim that Arcadia Biosciences can reach $4 in the near future.
What are Arcadia Biosciences's analysts' financial forecasts?
Arcadia Biosciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.95M (high $4.95M, low $4.95M), average EBITDA is $-4.95M (high $-4.95M, low $-4.95M), average net income is $-2.937M (high $-2.937M, low $-2.937M), average SG&A $21.36M (high $21.36M, low $21.36M), and average EPS is $-2.155 (high $-2.155, low $-2.155). RKDA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.55M (high $6.55M, low $6.55M), average EBITDA is $-6.55M (high $-6.55M, low $-6.55M), average net income is $-1.785M (high $-1.785M, low $-1.785M), average SG&A $28.26M (high $28.26M, low $28.26M), and average EPS is $-1.31 (high $-1.31, low $-1.31).
Did the RKDA's actual financial results beat the analysts' financial forecasts?
Based on Arcadia Biosciences's last annual report (Dec 2023), the company's revenue was $5.33M, which missed the average analysts forecast of $6.3M by -15.34%. Apple's EBITDA was $-13.938M, beating the average prediction of $-6.296M by 121.40%. The company's net income was $-13.981M, missing the average estimation of $-23.114M by -39.51%. Apple's SG&A was $14.51M, missing the average forecast of $27.16M by -46.59%. Lastly, the company's EPS was $-0.0113, missing the average prediction of $-16.96 by -99.93%. In terms of the last quarterly report (Sep 2023), Arcadia Biosciences's revenue was $1.6M, beating the average analysts' forecast of $1.55M by 3.33%. The company's EBITDA was $-3.242M, beating the average prediction of $-1.546M by 109.77%. Arcadia Biosciences's net income was $-2.567M, missing the average estimation of $-3.993M by -35.71%. The company's SG&A was $3.44M, missing the average forecast of $6.67M by -48.37%. Lastly, the company's EPS was $-1.89, missing the average prediction of $-2.93 by -35.49%